---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Safety questions"
description: "Safety questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Monitoring. Questions: What are the most common side effects of Skyrizi for plaque psoriasis? Does Skyrizi require lab monitoring for psoriasis? What are the long-term side effects of Skyrizi for psoriasis? Do patients develop antibodies to Skyrizi (immunogenicity)? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Safety questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications: Safety](https://www.evicenter.com/medical-information/skyrizi/safety).

## Side effects

<a id="skyrizi-side-effects"></a>

### What are the most common side effects of Skyrizi for plaque psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Adverse Reactions in Adults with Plaque Psoriasis 
> A total of 2234 subjects were treated with SKYRIZI in clinical development trials in plaque 
> psoriasis. Of these, 1208 subjects with psoriasis were exposed to SKYRIZI for at least one year.  
> Data from placebo- and active-controlled trials were pooled to evaluate the safety of SKYRIZI 
> for up to 16 weeks. In total, 1306 subjects were evaluated in the SKYRIZI 150 mg group.  
> Table 4 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher 
> rate in the SKYRIZI group than the placebo group during the 16-week controlled period of 
> pooled clinical trials.”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

> “Table 4. Adverse Reactions Occurring in ≥ 1% of Adults with Plaque Psoriasis on 
> SKYRIZI through Week 16 
> Adverse Drug Reactions 
> SKYRIZI 
> N = 1306 
> n (%) 
> Placebo 
> N = 300 
> n (%) 
> Upper respiratory infections<sup>a</sup> 
> 170 (13) 
> 29 (9.7) 
> Headache<sup>b</sup> 
> 46 (3.5) 
> 6 (2)  
> Fatigue<sup>c</sup> 
> 33 (2.5) 
> 3 (1) 
> Injection site reactions<sup>d</sup> 
> 19 (1.5) 
> 3 (1) 
> Tinea infections<sup>e</sup> 
> 15 (1.1) 
> 1 (0.3) 
> <sup>a</sup> Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, 
> nasopharyngitis, pharyngitis (including viral), tonsillitis 
> <sup>b</sup> Includes: headache, tension headache, sinus headache, cervicogenic headache  
> <sup>c</sup> Includes: fatigue, asthenia 
> <sup>d</sup> Includes: injection site bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, 
> irritation, pain, pruritus, reaction, swelling, warmth 
> <sup>e</sup> Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection, onychomycosis  
>
>
> Adverse reactions that occurred in < 1% but > 0.1% of subjects in the SKYRIZI group and at a 
> higher rate than in the placebo group through Week 16 were folliculitis and urticaria.”

Source: [SKYRIZI: Prescribing information, page 10, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=10)

> “Safety Through Week 52 
> Through Week 52, no new adverse reactions were identified, and the rates of the adverse 
> reactions were similar to those observed during the first 16 weeks of treatment. During this 
> period, serious infections that led to trial discontinuation included pneumonia.”

Source: [SKYRIZI: Prescribing information, page 10, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=10)

Note: Table 4 columns are SKYRIZI (N=1306) and placebo (N=300), in that order, as n (%).

<a id="skyrizi-long-term-safety"></a>

### What are the long-term side effects of Skyrizi for psoriasis?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Safety Through Week 52 
> Through Week 52, no new adverse reactions were identified, and the rates of the adverse 
> reactions were similar to those observed during the first 16 weeks of treatment. During this 
> period, serious infections that led to trial discontinuation included pneumonia.”

Source: [SKYRIZI: Prescribing information, page 10, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=10)

> “A total of 2234 subjects were treated with SKYRIZI in clinical development trials in plaque 
> psoriasis. Of these, 1208 subjects with psoriasis were exposed to SKYRIZI for at least one year.”

Source: [SKYRIZI: Prescribing information, page 9, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=9)

> “With SKYRIZI, rates of adverse events (AEs) at Week 52 were similar to those observed at Week 16. Overall long-term AE rates remained consistent up to ~9 years of exposure.<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=With%20SKYRIZI%2C%20rates%20of%20adverse,up%20to%20~9%20years%20of)

> “<sup>§</sup>Data are integrated from 23 Phase 1-4 clinical trials in Ps. Mean treatment duration was 3.2 years (9 days-9.1 years).<sup>2</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=are%20integrated%20from%2023%20Phase,was%203.2%20years%20%289%20days%2D9.1)

> “Long-term data include all administered doses ranging from 18 mg to 180 mg of SKYRIZI in 3,658 patients. The FDA-approved dose is 150 mg at Week 0, Week 4, and every 12 weeks thereafter.<sup>1,2</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=Long%2Dterm%20data%20include%20all%20administered,4%2C%20and%20every%2012%20weeks)

Note: The approximately 9-year statement is from a pooled analysis of all explored doses that the safety page cites as a 2025 conference poster (Gordon et al.); the Prescribing Information reports controlled safety data through Week 52.

<a id="skyrizi-antibodies"></a>

### Do patients develop antibodies to Skyrizi (immunogenicity)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “By Week 52, approximately 24% (263/1079) of adults treated with SKYRIZI at the 
> recommended dosage developed antibodies to risankizumab-rzaa. Of the subjects who developed 
> antibodies to risankizumab-rzaa, approximately 57% (14% of all subjects treated with SKYRIZI) 
> had antibodies that were classified as neutralizing. Higher antibody titers in approximately 1% of 
> subjects treated with SKYRIZI were associated with lower risankizumab-rzaa concentrations and 
> reduced clinical response.”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

> “In pediatric subjects 6 years of age and older, approximately 15% (13/88) of subjects treated with 
> SKYRIZI at the recommended dose developed antibodies to risankizumab-rzaa by Week 52. Of 
> the 13 subjects who developed antibodies to risankizumab-rzaa, approximately 15% (2.3% of all 
> subjects treated with SKYRIZI) had antibodies that were classified as neutralizing.”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

> “Due to the 
> small number of subjects who developed antibodies to risankizumab-rzaa, it is difficult to”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

> “determine the impact of the antibodies on pharmacokinetics, pharmacodynamics, safety, and/or 
> effectiveness.”

Source: [SKYRIZI: Prescribing information, page 21, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=21)

Note: The pediatric qualification continues across a page break of the Prescribing Information.

## Monitoring

<a id="skyrizi-lab-monitoring"></a>

### Does Skyrizi require lab monitoring for psoriasis?

> “CONSIDER EVALUATING PATIENTS FOR TB PRIOR TO INITIATION BASED ON CLINICAL JUDGMENT. INSTRUCT PATIENTS TO REPORT SIGNS AND SYMPTOMS OF INFECTION.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=CONSIDER%20EVALUATING%20PATIENTS%20FOR%20TB,SIGNS%20AND%20SYMPTOMS%20OF%20INFECTION.)

> “NO MANDATORY TB TEST.<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=SYMPTOMS%20OF%20INFECTION.-,NO%20MANDATORY%20TB)

> “NO ROUTINE LAB MONITORING REQUIRED DURING TREATMENT.<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Clinical Safety Profile for Ps & PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/pso-psa-safety-profile#:~:text=NO%20ROUTINE%20LAB%20MONITORING%20REQUIRED%20DURING)

> “For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin 
> at baseline, and during induction at least up to 12 weeks of treatment. Monitor thereafter 
> according to routine patient management.”

Source: [SKYRIZI: Prescribing information, page 8, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=8)

> “• For the treatment of moderately to severely active Crohn’s disease and ulcerative colitis, 
> obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI [see 
> Warnings and Precautions (5.4)].”

Source: [SKYRIZI: Prescribing information, page 3, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=3)

Note: The statements on TB evaluation and lab monitoring are from the safety page of the Skyrizi HCP site; the skyrizi-tuberculosis question covers TB evaluation. The liver test schedule in the Prescribing Information applies to Crohn’s disease and ulcerative colitis.

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
